Premium
CD 30‐positive transformed follicular lymphoma: two case reports and literature review
Author(s) -
MontesMoreno Santiago,
Climent Fina,
González de Villambrosía Sonia,
González Barca Eva M,
Batlle Ana,
Insunza Andrés,
PanéFoix María,
Colorado Mercedes,
MartinSánchez Guillermo,
Espiga Carlos Richard,
Conde Eulogio,
Piris Miguel A
Publication year - 2015
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.12733
Subject(s) - cd30 , follicular lymphoma , lymphoma , prednisone , rituximab , follicular phase , vincristine , medicine , cyclophosphamide , b cell lymphoma , large cell , pathology , cancer research , chemotherapy , cancer , adenocarcinoma
Aims Here we report two cases of follicular lymphoma that transformed to CD 30 positive diffuse large B cell lymphoma and review the literature on this topic. Results The first case represents an example of early transformation of conventional low‐grade follicular lymphoma to CD 30‐positive large B cell lymphoma. Immunoglobulin (Ig)H and cytogenetic identity was demonstrated between both components. High‐dose and auto‐stem cell transplant ( SCT ) was applied and complete response was achieved. The second case represents an example of d'emblee transformation of intrafollicular neoplasia to CD 30‐positive large B cell lymphoma. Immunoglobulin K deleting element (IgKde) and cytogenetic identity between both phases was demonstrated. The patient was in partial response after four cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R‐ CHOP ). Conclusions CD 30 expression was found to be associated in these cases to the transformation event and could be considered a therapeutic target to add to conventional immunochemotherapeutic regimens, even in combination with auto‐ SCT . We suggest looking for CD 30 expression in transformed follicular lymphoma cases.